Search results for "Platelet"

showing 10 items of 786 documents

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment

2008

The discovery of the Janus kinase 2 Val617Phe mutation has brought new insights into the development of myeloproliferative disorders; however, the pathogenesis of essential thrombocythemia and its related thrombotic complications has not been completely understood. Although the Janus kinase 2 Val617Phe mutation confirms the initially suspected clonal character of the disease, factors influencing clonal transformation and expansion in the bone marrow have not been fully detected. Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, comp…

Adultmedicine.medical_specialtyMutation MissenseOral contraceptiveEssential thrombocythemiaGastroenterologyContraceptives Oral HormonalPathogenesisMesenteric VeinsPortal thrombosisMyeloproliferative DisordersInternal medicinemedicineHumansPlateletSplanchnic CirculationJanus kinase 2Janus kinase 2biologyessential thrombocythemia Janus kinase 2 oral contraceptives portal thrombosisKinaseEssential thrombocythemiaVascular diseasebusiness.industryThrombosisHematologyGeneral Medicinemedicine.diseaseThrombocytopeniaThrombosisEndocrinologybiology.proteinFemalebusiness
researchProduct

Patent foramen ovale closure in stroke patients with migraine in the CLOSE trial. The CLOSE-MIG study.

2021

International audience; Background and purpose The efficacy of patent foramen ovale (PFO) closure to reduce the frequency of migraine attacks remains controversial. Methods This was a planned sub-study in migraine patients enrolled in a randomized, clinical trial designed to assess the superiority of PFO closure plus antiplatelet therapy over antiplatelet therapy alone to prevent stroke recurrence in patients younger than 60 years with a PFO-associated cryptogenic ischaemic stroke. The main outcome was the mean annual number of migraine attacks in migraine patients with aura and in those without aura, as recorded at each follow-up visit by study neurologists. Results Of 473 patients randomi…

Adultmedicine.medical_specialtyStroke patientAuraSeptal Occluder Device[SDV]Life Sciences [q-bio]Migraine DisordersForamen Ovale PatentBrain Ischemia03 medical and health sciences0302 clinical medicineInternal medicineIschaemic strokemedicineHumans030212 general & internal medicineClosure (psychology)Foramen ovale (heart)business.industryMiddle Agedmedicine.diseaseClinical trialStrokemedicine.anatomical_structureTreatment OutcomeNeurologyMigraineCardiologyPatent foramen ovaleFemaleNeurology (clinical)business030217 neurology & neurosurgeryPlatelet Aggregation InhibitorsEuropean journal of neurologyREFERENCES
researchProduct

Growth factor concentrations and their placental mRNA expression are modulated in gestational diabetes mellitus: possible interactions with macrosomia

2009

Abstract Background Gestational diabetes mellitus (GDM) is a form of diabetes that occurs during pregnancy. GDM is a well known risk factor for foetal overgrowth, termed macrosomia which is influenced by maternal hypergycemia and endocrine status through placental circulation. The study was undertaken to investigate the implication of growth factors and their receptors in GDM and macrosomia, and to discuss the role of the materno-foeto-placental axis in the in-utero regulation of foetal growth. Methods 30 women with GDM and their 30 macrosomic babies (4.75 ± 0.15 kg), and 30 healthy age-matched pregnant women and their 30 newborns (3.50 ± 0.10 kg) were recruited in the present study. Serum …

Adultmedicine.medical_specialtyTunisiaendocrine system diseasesOffspringPlacentalcsh:Gynecology and obstetricsFetal MacrosomiaReceptor Platelet-Derived Growth Factor betaGrowth factor receptorEpidermal growth factorPregnancyPlacentaDiabetes mellitusInternal medicineResearch articleObstetrics and GynaecologyFetal macrosomiamedicineHumansRNA MessengerInsulin-Like Growth Factor Ilcsh:RG1-991PregnancyEpidermal Growth Factorbusiness.industryInfant NewbornObstetrics and Gynecologynutritional and metabolic diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsUp-RegulationGestational diabetesDiabetes Gestationalmedicine.anatomical_structureEndocrinologyInsulin-Like Growth Factor Binding Protein 3Case-Control StudiesGrowth HormoneIntercellular Signaling Peptides and ProteinsFemaleFibroblast Growth Factor 2businessBMC Pregnancy and Childbirth
researchProduct

Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

2019

Abstract Background Systemic sclerosis is a systemic connective tissue disease characterized by endothelium damage, fibrosis, and subsequent atrophy of the skin. Perioral fibrosis produces a characteristic microstomia together with microcheilia, both of which cause severe difficulties and affects patients’ daily life, such as eating and oral hygiene. Since there are no effective and specific therapies, we have aimed at evaluating the response to filler injections of hyaluronic acid together with platelet-rich plasma. Methods Ten female patients aged between 18 and 70 were included in this study. Each patient was treated with three filler injections of hyaluronic acid and platelet-rich plasm…

Adultmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHyaluronic acidMicrocheiliaGastroenterologySystemic sclerosi030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtrophyPlatelet-rich plasmaFibrosisInternal medicineHyaluronic acidmedicineHumansProspective StudiesHyaluronic acid; Platelet-rich plasma; Systemic sclerosis; TherapySkin030203 arthritis & rheumatologyScleroderma SystemicViscosupplementsMicrostomiabusiness.industryMiddle Agedmedicine.diseaseConnective tissue diseaseElasticityLipRheumatologySettore MED/16 - ReumatologiaTreatment OutcomechemistryPlatelet-rich plasmaQuality of LifeSystemic sclerosisFemaleTherapylcsh:RC925-935businessResearch ArticleArthritis Research & Therapy
researchProduct

The impact of del Nido cardioplegia solution on blood morphology parameters

2021

Background: Crystalloid cardioplegic solutions are believed to reduce hemoglobin significantly and increase the transfusion rate. However, recent reports indicate that the del Nido cardioplegia may preserve blood morphology parameters. Methods: In “The del Nido versus cold blood cardioplegia in aortic valve Replacement” trial patients undergoing aortic valve replacement were randomized into the del Nido (DN) or cold blood cardioplegia (CB) group. For the subanalysis, patients who underwent blood transfusions were excluded from the study. Red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count and platelet (PLT) count were measured before the surgery, 24-, 48-, and 96 hours post…

Advanced and Specialized Nursingmedicine.diagnostic_testbusiness.industryGeneral Medicinemedicine.diseaseRed blood cellmedicine.anatomical_structureAortic valve replacementBlood productAnesthesiaWhite blood cellCoagulopathyMedicineRadiology Nuclear Medicine and imagingPlateletHemoglobinCardiology and Cardiovascular MedicinebusinessSafety ResearchPartial thromboplastin timePerfusion
researchProduct

Abstract TMP17: Revacept, an Inhibitor of Platelet Adhesion in Patients With Symptomatic Carotid Artery Stenosis. Safety Data From the International …

2020

Introduction: Revacept is a novel vascular lesion-directed inhibitor of platelet adhesion and thrombus formation, exhibiting no effects on the homeostatic functions of circulating platelets. Objective: The effects of Revacept on plaque-mediated thrombosis were investigated in patients with symptomatic stenosis of the internal carotid artery (at least 50%, following ECST-criteria). Methods: Within an international, prospective, multicenter (n=16), randomized trial 158 patients could be randomized to receive placebo, or 40/120 mg Revacept by intravenous infusion over 20 minutes. Cerebrovascular events and cardiovascular complications were followed up to 3 months. Results: 158 patients were f…

Advanced and Specialized Nursingmedicine.medical_specialtybusiness.industryPlatelet adhesionmedicine.medical_treatmentSymptomatic carotid artery stenosisPhases of clinical researchStentCarotid endarterectomymedicine.diseaseInternal medicinemedicineCardiologyPlateletIn patientNeurology (clinical)ThrombusCardiology and Cardiovascular MedicinebusinessStroke
researchProduct

Platelets, eicosanoids and aging.

1992

Aged 80 and overBlood Plateletsmedicine.medical_specialtyAgingPlatelet AggregationGeriatrics gerontologybusiness.industrymedicine.diseaseThrombosisEndocrinologyInternal medicinemedicineBlood VesselsEicosanoidsHumansPlateletGeriatrics and GerontologybusinessAgedAging (Milan, Italy)
researchProduct

Oxidative Stress and Mitochondrial Damage in Neurodegenerative Diseases: From Molecular Mechanisms to Targeted Therapies

2020

The progression of Alzheimer's dementia is associated with neurovasculature impairment, which includes inflammation, microthromboses, and reduced cerebral blood flow. Here, we investigate the effects of β amyloid peptides on the function of platelets, the cells driving haemostasis. Amyloid peptide β1-42 (Aβ1-42), Aβ1-40, and Aβ25-35 were tested in static adhesion experiments, and it was found that platelets preferentially adhere to Aβ1-42 compared to other Aβ peptides. In addition, significant platelet spreading was observed over Aβ1-42, while Aβ1-40, Aβ25-35, and the scAβ1-42 control did not seem to induce any platelet spreading, which suggested that only Aβ1-42 activates platelet signalli…

AgingArticle SubjectPlatelet Glycoprotein GPIIb-IIIa Complexmedicine.disease_causeBiochemistryOxidative Stress Mitochondria Neurodegenerative DiseasesText miningMedicineHumansPlatelet activationQH573-671business.industryNADPH OxidasesNeurodegenerative DiseasesThrombosisCell BiologyGeneral Medicinemedicine.diseasePlatelet ActivationThrombosisPlatelet Glycoprotein GPIIb-IIIa ComplexOxidative StressCancer researchCytologybusinessOxidative stressResearch ArticleOxidative Medicine and Cellular Longevity
researchProduct

Prostacyclin receptor desensitization is a reversible phenomenon in human platelets.

1997

Background Long-term exposure of platelets to endogenous or exogenous prostacyclin or its analogues might result in desensitization of the platelet prostacyclin receptor in vitro and in vivo accompanied by a loss in receptor density on the platelet surface and a reduced sensitivity toward the inhibitory effects of prostacyclins. However, the reversibility of this process in platelets has not yet been investigated. Methods and Results Human platelets desensitized by the chemically stable prostacyclin analogue iloprost showed a significant reduction in [ 3 H]-iloprost binding sites that was reversed by saponin permeabilization. This indicates functionally active internalized prostacyclin rec…

AgonistBlood PlateletsMalemedicine.medical_specialtyCell Membrane Permeabilitymedicine.drug_classReceptors ProstaglandinProstaglandinProstacyclinReceptors EpoprostenolProstacyclin receptor bindingchemistry.chemical_compoundReference ValuesPhysiology (medical)Internal medicinemedicineCyclic AMPHumansPlateletIloprostProstacyclin receptorbusiness.industryEndocrinologychemistrycardiovascular systemPlatelet aggregation inhibitorlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugIloprostCirculation
researchProduct

Platelet Reactivity in Hemophilia a. Flow Cytometry Study to Detect the Hemorragic Phenotype

2016

Abstract INTRODUCTION Hemophilia A (HA) is a rare inherited genetic disorder linked to the X chromosome, characterized by joint bleeding in patients with severe disease with <1% of factor VIII (FVIII)(White et al. Thromb Haemost 2001). However, there are cases of severe HA with less bleeding than usual and it has been postulated that there must be other contributors to the hemorrhagic phenotype, including a platelet dysfunction (Van Bladel et al. Haematologica 2011). In this study we analyzed platelet reactivity in a cohort of 16 male patients with severe HA in prophylactic treatment by flow cytometry. The control group was 15 healthy male subjects. METHODS A longitudinal prospective obs…

Agonistmedicine.medical_specialtyVenipuncturemedicine.diagnostic_testmedicine.drug_classbusiness.industryImmunologyCell BiologyHematologyBiochemistryGastroenterologyFlow cytometryBasal (phylogenetics)Internal medicineStatistical significanceImmunologymedicinePlateletPlatelet activationbusinessWhole bloodBlood
researchProduct